Evaluating adverse events of antibacterials in infants: insights from FDA adverse event reporting system (FAERS) data
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026
DOI: 10.1007/s00210-025-04868-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Kai Yan und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Management, Shanxi Medical University, Taiyuan, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Adverse Drug Reaction Reporting Systems, Gentamicins, Vancomycin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Special fund for Science and Technology Innovation Teams of Shanxi Province, Fundamental Research Program of Shanxi Province.
Themen: Patientensicherheit
Abstract (Originalsprache)
This study addresses a significant gap in evaluations of the safety of antibacterial drugs in infants aged 0-1 year on the basis of a comprehensive pharmacovigilance analysis. We use data spanning the period from 2005Q1 to 2025Q1, which we obtain from the FDA Adverse Event Reporting System (FAERS) to retrospectively assess adverse events (AEs) associated with three commonly used antibacterials-vancomycin, cefotaxime, and gentamicin-in this vulnerable population. A total of 698 cases of AE were included in the study. Disproportionality analyses (which rely on the reporting odds ratio (ROR), proportional odds ratio (PRR), Bayesian confidence propagation neural network (BCPN), and multi-item gamma Poisson shrinker (MGPS)) revealed significant AE signals with multiple testing correction using a 5% false discovery rate: vancomycin and gentamicin were predominantly associated with acute kidney injury (n = 50, ROR = 16.18, 95% CI 12.13-21.59, P = 3.16e - 41; n = 12, ROR = 21.18, 95% CI 11.82-37.95, P = 1.95e - 12), whereas cefotaxime was linked to increased alanine aminotransferase (n = 4, ROR = 7.72, 95% CI 2.87-20.75, P = 0.002) and aspartate aminotransferase levels (n = 4, ROR = 7.51, 95% CI 2.79-20.19, P = 0.002), thus indicating liver injury. Gentamicin was also associated with neurosensory deafness (n = 6, ROR = 146.47, 95% CI 63.31-338.83, P = 8.85e - 12). A Weibull distribution analysis of onset timing showed that the risk of AEs for all three antibacterials remained consistent over time. These findings underscore the increased vulnerability of infants to drug toxicity. These results emphasize the critical need for cautious, individualized risk-benefit assessments in the context of prescribing antibacterials to infant patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Management, Shanxi Medical University, Taiyuan, China.
- Shanxi Key Laboratory of Big Data for Clinical Decision, Shanxi Medical University, Taiyuan, China.
- Department of Information Technology, Digital Health Guidance Center of Shanxi Province, Taiyuan, China.
- Department of Pediatrics, Shanxi Medical University, Taiyuan, China.
- Department of Anesthesiology, Second Hospital of Shanxi Medical University, Taiyuan, China.
- Department of Anesthesiology, Shanxi Provincial People's Hospital (Fifth Hospital) of Shanxi Medical University, Taiyuan, China.
Förderung
- National Natural Science Foundation of China
- Special fund for Science and Technology Innovation Teams of Shanxi Province
- Fundamental Research Program of Shanxi Province
Zitieren
APA
Yan, K., Yang, G., Yan, L., Wu, L., Wang, Y., He, P., & Yu, Q. (2026). Evaluating adverse events of antibacterials in infants: insights from FDA adverse event reporting system (FAERS) data. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04868-4
Vancouver
Yan K, Yang G, Yan L, Wu L, Wang Y, He P, et al. Evaluating adverse events of antibacterials in infants: insights from FDA adverse event reporting system (FAERS) data. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-025-04868-4
BibTeX
@article{Yan2026,
author = {Yan, Kai and Yang, Guang and Yan, Lixuan and Wu, Li and Wang, Yang and He, Peifeng and Yu, Qi},
title = {Evaluating adverse events of antibacterials in infants: insights from FDA adverse event reporting system (FAERS) data},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
doi = {10.1007/s00210-025-04868-4}
}
EUVIMED